The genetics of kidney stone disease and nephrocalcinosis.
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
17
11
2021
pubmed:
16
12
2021
medline:
28
4
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approximately 10% of adults worldwide, and the incidence of stone disease is increasing. Kidney stone formation results from an imbalance of inhibitors and promoters of crystallization, and calcium-containing calculi account for over 80% of stones. In most patients, the underlying aetiology is thought to be multifactorial, with environmental, dietary, hormonal and genetic components. The advent of high-throughput sequencing techniques has enabled a monogenic cause of kidney stones to be identified in up to 30% of children and 10% of adults who form stones, with ~35 different genes implicated. In addition, genome-wide association studies have implicated a series of genes involved in renal tubular handling of lithogenic substrates and of inhibitors of crystallization in stone disease in the general population. Such findings will likely lead to the identification of additional treatment targets involving underlying enzymatic or protein defects, including but not limited to those that alter urinary biochemistry.
Identifiants
pubmed: 34907378
doi: 10.1038/s41581-021-00513-4
pii: 10.1038/s41581-021-00513-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
224-240Informations de copyright
© 2021. Springer Nature Limited.
Références
Scales, C. D. Jr, Smith, A. C., Hanley, J. M. & Saigal, C. S. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160–165 (2012).
pubmed: 22498635
pmcid: 3362665
doi: 10.1016/j.eururo.2012.03.052
Tasian, G. E. et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin. J. Am. Soc. Nephrol. 11, 488–496 (2016).
pubmed: 26769765
pmcid: 4791823
doi: 10.2215/CJN.07610715
Stamatelou, K. K., Francis, M. E., Jones, C. A., Nyberg, L. M. & Curhan, G. C. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 63, 1817–1823 (2003).
pubmed: 12675858
doi: 10.1046/j.1523-1755.2003.00917.x
Romero, V., Akpinar, H. & Assimos, D. G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev. Urol. 12, e86–e96 (2010).
pubmed: 20811557
pmcid: 2931286
Sorokin, I. et al. Epidemiology of stone disease across the world. World J. Urol. 35, 1301–1320 (2017).
pubmed: 28213860
doi: 10.1007/s00345-017-2008-6
Sas, D. J. An update on the changing epidemiology and metabolic risk factors in pediatric kidney stone disease. Clin. J. Am. Soc. Nephrol. 6, 2062–2068 (2011).
pubmed: 21737846
doi: 10.2215/CJN.11191210
Dwyer, M. E. et al. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J. Urol. 188, 247–252 (2012).
pubmed: 22595060
pmcid: 3482509
doi: 10.1016/j.juro.2012.03.021
Lieske, J. C. et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 69, 760–764 (2006).
pubmed: 16518332
doi: 10.1038/sj.ki.5000150
Scales, C. D.Jr et al. Urinary stone disease: advancing knowledge, patient care, and population health. Clin. J. Am. Soc. Nephrol. 11, 1305–1312 (2016).
pubmed: 26964844
pmcid: 4934851
doi: 10.2215/CJN.13251215
Rule, A. D. et al. Kidney stones and the risk for chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 804–811 (2009).
pubmed: 19339425
pmcid: 2666438
doi: 10.2215/CJN.05811108
Jeong, I. G. et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am. J. Kidney Dis. 58, 383–388 (2011).
pubmed: 21620546
doi: 10.1053/j.ajkd.2011.03.021
Reiner, A. P. et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J. Urol. 185, 920–925 (2011).
pubmed: 21251678
doi: 10.1016/j.juro.2010.10.086
Dhondup, T. et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am. J. Kidney Dis. 72, 790–797 (2018).
pubmed: 30146423
pmcid: 6252145
doi: 10.1053/j.ajkd.2018.06.012
Rule, A. D., Krambeck, A. E. & Lieske, J. C. Chronic kidney disease in kidney stone formers. Clin. J. Am. Soc. Nephrol. 6, 2069–2075 (2011).
pubmed: 21784825
pmcid: 3156433
doi: 10.2215/CJN.10651110
Ziemba, J. B. & Matlaga, B. R. Epidemiology and economics of nephrolithiasis. Investig. Clin. Urol. 58, 299–306 (2017).
pubmed: 28868500
pmcid: 5577325
doi: 10.4111/icu.2017.58.5.299
Singh, P. et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin. Proc. 90, 1356–1365 (2015).
pubmed: 26349951
doi: 10.1016/j.mayocp.2015.07.016
Coe, F. L., Worcester, E. M. & Evan, A. P. Idiopathic hypercalciuria and formation of calcium renal stones. Nat. Rev. Nephrol. 12, 519–533 (2016).
pubmed: 27452364
pmcid: 5837277
doi: 10.1038/nrneph.2016.101
Evan, A. P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 25, 831–841 (2010).
pubmed: 19198886
doi: 10.1007/s00467-009-1116-y
Robertson, W. G., Peacock, M., Marshall, R. W., Marshall, D. H. & Nordin, B. E. C. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N. Engl. J. Med. 294, 249–252 (1976).
pubmed: 1244550
doi: 10.1056/NEJM197601292940504
Parks, J. H., Coward, M. & Coe, F. L. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 51, 894–900 (1997).
pubmed: 9067927
doi: 10.1038/ki.1997.126
Finlayson, B. & Reid, S. The expectation of free and fixed particles in urinary stone disease. Invest. Urol. 15, 442–448 (1978).
pubmed: 649291
Evan, A. P. et al. Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat. Rec. 290, 1315–1323 (2007).
doi: 10.1002/ar.20580
Randall, A. An hypothesis for the origin of renal calculus. N. Engl. J. Med 214, 234–242 (1936).
doi: 10.1056/NEJM193602062140603
Khan, S. R. & Canales, B. K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43 (Suppl 1), 109–123 (2015).
pubmed: 25119506
doi: 10.1007/s00240-014-0705-9
Evan, A. P. et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 67, 576–591 (2005).
pubmed: 15673305
doi: 10.1111/j.1523-1755.2005.67114.x
Evan, A. P. et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 69, 2227–2235 (2006).
pubmed: 16710357
doi: 10.1038/sj.ki.5000268
Evan, A. P., Worcester, E. M., Coe, F. L., Williams, J. Jr. & Lingeman, J. E. Mechanisms of human kidney stone formation. Urolithiasis 43 (Suppl 1), 19–32 (2015).
pubmed: 25108546
doi: 10.1007/s00240-014-0701-0
Coe, F. L., Evan, A. P., Worcester, E. M. & Lingeman, J. E. Three pathways for human kidney stone formation. Urological Res. 38, 147–160 (2010).
doi: 10.1007/s00240-010-0271-8
Evan, A. P. et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111, 602–605 (2003).
doi: 10.1172/JCI17038
Khan, S. R. et al. Kidney stones. Nat. Rev. Dis. Prim. 3, 17001 (2017).
pubmed: 28079115
doi: 10.1038/nrdp.2017.1
Evan, A. P., Lingeman, J. E., Coe, F. L. & Worcester, E. M. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin. Nephrol. 28, 111–119 (2008).
pubmed: 18359392
pmcid: 2329574
doi: 10.1016/j.semnephrol.2008.01.004
Chuang, T. F. et al. Risk of chronic kidney disease in patients with kidney stones — a nationwide cohort study. BMC Nephrol. 21, 292 (2020).
pubmed: 32698782
pmcid: 7376912
doi: 10.1186/s12882-020-01950-2
Jungers, P., Joly, D., Barbey, F., Choukroun, G. & Daudon, M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am. J. Kidney Dis. 44, 799–805 (2004).
pubmed: 15492945
doi: 10.1016/S0272-6386(04)01131-X
Worcester, E. M., Parks, J. H., Evan, A. P. & Coe, F. L. Renal function in patients with nephrolithiasis. J. Urol. 176, 600–603 (2006). discussion 603.
pubmed: 16813897
doi: 10.1016/j.juro.2006.03.095
Rule, A. D. et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int. 67, 2376–2382 (2005).
pubmed: 15882282
doi: 10.1111/j.1523-1755.2005.00344.x
Kersse, K., Bertrand, M. J., Lamkanfi, M. & Vandenabeele, P. NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor. Rev. 22, 257–276 (2011).
pubmed: 21996492
doi: 10.1016/j.cytogfr.2011.09.003
Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J. Clin. Invest. 123, 236–246 (2013).
pubmed: 23221343
doi: 10.1172/JCI63679
Ware, E. B. et al. Genome-wide association study of 24-H urinary excretion of calcium, magnesium, and uric acid. Mayo Clin. Proc. Innov. Qual. Outcomes 3, 448–460 (2019).
pubmed: 31993563
pmcid: 6978610
doi: 10.1016/j.mayocpiqo.2019.08.007
Lieske, J. C. & Wang, X. Heritable traits that contribute to nephrolithiasis. Urolithiasis 47, 5–10 (2019).
pubmed: 30460525
doi: 10.1007/s00240-018-1095-1
Trinchieri, A., Mandressi, A., Luongo, P., Coppi, F. & Pisani, E. Familial aggregation of renal calcium stone disease. J. Urol. 139, 478–481 (1988).
pubmed: 3343730
doi: 10.1016/S0022-5347(17)42497-9
Curhan, G. C., Willett, W. C., Rimm, E. B. & Stampfer, M. J. Family history and risk of kidney stones. J. Am. Soc. Nephrol. 8, 1568–1573 (1997).
pubmed: 9335385
doi: 10.1681/ASN.V8101568
Resnick, M., Pridgen, D. B. & Goodman, H. O. Genetic predisposition to formation of calcium oxalate renal calculi. N. Engl. J. Med. 278, 1313–1318 (1968).
pubmed: 5648597
doi: 10.1056/NEJM196806132782403
McGeown, M. G. Heredity in renal stone disease. Clin. Sci. 19, 465–471 (1960).
pubmed: 13773937
Goldfarb, D. S., Fischer, M. E., Keich, Y. & Goldberg, J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) registry. Kidney Int. 67, 1053–1061 (2005).
pubmed: 15698445
doi: 10.1111/j.1523-1755.2005.00170.x
Goldfarb, D. S., Avery, A. R., Beara-Lasic, L., Duncan, G. E. & Goldberg, J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int. Rep. 4, 535–540 (2019).
pubmed: 30993229
doi: 10.1016/j.ekir.2018.11.017
Sayer, J. A. Progress in understanding the genetics of calcium-containing nephrolithiasis. J. Am. Soc. Nephrol. 28, 748–759 (2017).
pubmed: 27932479
doi: 10.1681/ASN.2016050576
Stechman, M. J., Loh, N. Y. & Thakker, R. V. Genetic causes of hypercalciuric nephrolithiasis. Pediatr. Nephrol. 24, 2321–2332 (2009).
pubmed: 18446382
doi: 10.1007/s00467-008-0807-0
Goldfarb, D. S. The exposome for kidney stones. Urolithiasis 44, 3–7 (2016).
pubmed: 26615595
doi: 10.1007/s00240-015-0847-4
Monico, C. G. & Milliner, D. S. Genetic determinants of urolithiasis. Nat. Rev. Nephrol. 8, 151–162 (2012).
doi: 10.1038/nrneph.2011.211
Griffin, D. G. A review of the heritability of idiopathic nephrolithiasis. J. Clin. Pathol. 57, 793–796 (2004).
pubmed: 15280397
pmcid: 1770398
doi: 10.1136/jcp.2003.014886
Hunter, D. J. et al. Genetic contribution to renal function and electrolyte balance: a twin study. Clin. Sci. 103, 259–265 (2002).
doi: 10.1042/cs1030259
Whitfield, J. B. & Martin, N. G. The effects of inheritance on constituents of plasma: a twin study on some biochemical variables. Ann. Clin. Biochem. 21, 176–183 (1984).
pubmed: 6541017
doi: 10.1177/000456328402100303
Moulin, F. et al. A population-based approach to assess the heritability and distribution of renal handling of electrolytes. Kidney Int. 92, 1536–1543 (2017).
pubmed: 28888328
doi: 10.1016/j.kint.2017.06.020
Ketha, H. et al. Altered calcium and vitamin d homeostasis in first-time calcium kidney stone-formers. PLoS One 10, e0137350 (2015).
pubmed: 26332888
pmcid: 4558059
doi: 10.1371/journal.pone.0137350
Wjst, M., Altmuller, J., Braig, C., Bahnweg, M. & Andre, E. A genome-wide linkage scan for 25-OH-D(3) and 1,25-(OH)2-D3 serum levels in asthma families. J. Steroid Biochem. Mol. Biol. 103, 799–802 (2007).
pubmed: 17236760
doi: 10.1016/j.jsbmb.2006.12.053
Karohl, C. et al. Heritability and seasonal variability of vitamin D concentrations in male twins. Am. J. Clin. Nutr. 92, 1393–1398 (2010).
pubmed: 20943799
pmcid: 2980965
doi: 10.3945/ajcn.2010.30176
van Dongen, J., Willemsen, G., Chen, W. M., de Geus, E. J. & Boomsma, D. I. Heritability of metabolic syndrome traits in a large population-based sample. J. Lipid Res. 54, 2914–2923 (2013).
pubmed: 23918046
pmcid: 3770104
doi: 10.1194/jlr.P041673
Coe, F. L. & Parks, J. H. in Nephrolithiasis: Pathogenesis and Treatment 108–138 (Year Book Medical Publishers, 1988).
Moe, O. W. & Bonny, O. Genetic hypercalciuria. J. Am. Soc. Nephrol. 16, 729–745 (2005).
pubmed: 15689405
doi: 10.1681/ASN.2004100888
Lieske, J. C., Turner, S. T., Edeh, S. N., Smith, J. A. & Kardia, S. L. Heritability of urinary traits that contribute to nephrolithiasis. Clin. J. Am. Soc. Nephrol. 9, 943–950 (2014).
pubmed: 24578335
pmcid: 4011445
doi: 10.2215/CJN.08210813
Tessier, J. et al. A family-based study of metabolic phenotypes in calcium urolithiasis. Kidney Int. 60, 1141–1147 (2001).
pubmed: 11532110
doi: 10.1046/j.1523-1755.2001.0600031141.x
Loredo-Osti, J. C. et al. Segregation of urine calcium excretion in families ascertained for nephrolithiasis: evidence for a major gene. Kidney Int. 68, 966–971 (2005).
pubmed: 16105027
doi: 10.1111/j.1523-1755.2005.00490.x
Nicar, M. J., Skurla, C., Sakhaee, K. & Pak, C. Y. C. Low urinary citrate excretion in nephrolithiasis. Urology 21, 8–13 (1983).
pubmed: 6823713
doi: 10.1016/0090-4295(83)90113-9
Zuckerman, J. M. & Assimos, D. G. Hypocitraturia: pathophysiology and medical management. Rev. Urol. 11, 134–144 (2009).
pubmed: 19918339
pmcid: 2777061
Monga, M., Macias, B., Groppo, E. & Hargens, A. Genetic heritability of urinary stone risk in identical twins. J. Urol. 175, 2125–2128 (2006).
pubmed: 16697817
doi: 10.1016/S0022-5347(06)00272-2
Taylor, E. N., Fung, T. T. & Curhan, G. C. DASH-style diet associates with reduced risk for kidney stones. J. Am. Soc. Nephrol. 20, 2253–2259 (2009).
pubmed: 19679672
pmcid: 2754098
doi: 10.1681/ASN.2009030276
Nouvenne, A. et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am. J. Clin. Nutr. 91, 565–570 (2010).
pubmed: 20042524
doi: 10.3945/ajcn.2009.28614
Sorensen, M. D. et al. Dietary intake of fiber, fruit and vegetables decreases the risk of incident kidney stones in women: a Women’s Health Initiative report. J. Urol. 192, 1694–1699 (2014).
pubmed: 24859445
pmcid: 4241174
doi: 10.1016/j.juro.2014.05.086
Lieske, J. C. et al. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J. Nephrol. 29, 45–51 (2016).
pubmed: 25963767
doi: 10.1007/s40620-015-0204-2
Martin, L. J., Lee, S. Y., Couch, S. C., Morrison, J. & Woo, J. G. Shared genetic contributions of fruit and vegetable consumption with BMI in families 20 y after sharing a household. Am. J. Clin. Nutr. 94, 1138–1143 (2011).
pubmed: 21831991
pmcid: 3173028
doi: 10.3945/ajcn.111.015461
de Castro, J. M. A twin study of genetic and environmental influences on the intake of fluids and beverages. Physiol. Behav. 54, 677–687 (1993).
pubmed: 8248345
doi: 10.1016/0031-9384(93)90076-R
de Castro, J. M. Independence of genetic influences on body size, daily intake, and meal patterns of humans. Physiol. Behav. 54, 633–639 (1993).
pubmed: 8248339
doi: 10.1016/0031-9384(93)90070-V
Pearle, M. S. et al. Medical management of kidney stones: AUA guideline. J. Urol. 192, 316–324 (2014).
pubmed: 24857648
doi: 10.1016/j.juro.2014.05.006
Rule, A. D., Lieske, J. C. & Pais, V. M. Jr Management of kidney stones in 2020. JAMA 323, 1961–1962 (2020).
pubmed: 32191284
doi: 10.1001/jama.2020.0662
Chillaron, J. et al. Pathophysiology and treatment of cystinuria. Nat. Rev. Nephrol. 6, 424–434 (2010).
pubmed: 20517292
doi: 10.1038/nrneph.2010.69
Turk, C. et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur. Urol. 69, 468–474 (2016).
pubmed: 26318710
doi: 10.1016/j.eururo.2015.07.040
Halbritter, J. et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J. Am. Soc. Nephrol. 26, 543–551 (2015).
pubmed: 25296721
doi: 10.1681/ASN.2014040388
Edvardsson, V. O. et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr. Nephrol. 28, 1923–1942 (2013).
pubmed: 23334384
pmcid: 4138059
doi: 10.1007/s00467-012-2329-z
Braun, D. A. et al. Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin. J. Am. Soc. Nephrol. 11, 664–672 (2016).
pubmed: 26787776
pmcid: 4822665
doi: 10.2215/CJN.07540715
Daga, A. et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 93, 204–213 (2018).
pubmed: 28893421
doi: 10.1016/j.kint.2017.06.025
Dent, C. E. & Friedman, M. Hypercalciuric rickets associated with renal tubular damage. Arch. Dis. Child. 39, 240–249 (1964).
pubmed: 14169453
pmcid: 2019188
doi: 10.1136/adc.39.205.240
Thakker, R. V. Pathogenesis of Dent’s disease and related syndromes of X-linked nephrolithiasis. Kidney Int. 57, 787–793 (2000).
pubmed: 10720930
doi: 10.1046/j.1523-1755.2000.00916.x
Pook, M. A. et al. Dent’s disease, a renal Fanconi syndrome and nephrocalcinosis and kidney stones, is associated with a microdeletion involving DXS255 and maps to Xp11.22 by linkage studies. Hum. Mol. Genet. 2, 2129–2134 (1993).
pubmed: 8111383
doi: 10.1093/hmg/2.12.2129
Dickson, F. J. & Sayer, J. A. Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition. Int. J. Mol. Sci. 21, 369 (2020).
pmcid: 6981752
doi: 10.3390/ijms21010369
Ehlayel, A. M. & Copelovitch, L. Update on Dent disease. Pediatr. Clin. North. Am. 66, 169–178 (2019).
pubmed: 30454742
doi: 10.1016/j.pcl.2018.09.003
Claverie-Martin, F., Ramos-Trujillo, E. & Garcia-Nieto, V. Dent’s disease: clinical features and molecular basis. Pediatr. Nephrol. 26, 693–704 (2011).
pubmed: 20936522
doi: 10.1007/s00467-010-1657-0
Lieske, J. C. et al. in GeneReviews® (eds Adam, M. P. et al.) (University of Washington, 1993).
Bockenhauer, D. et al. Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clin. J. Am. Soc. Nephrol. 3, 1430–1436 (2008).
pubmed: 18480301
pmcid: 2518783
doi: 10.2215/CJN.00520108
De Matteis, M. A., Staiano, L., Emma, F. & Devuyst, O. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2. Nat. Rev. Nephrol. 13, 455–470 (2017).
pubmed: 28669993
doi: 10.1038/nrneph.2017.83
Devuyst, O. & Thakker, R. V. Dent’s disease. Orphanet J. Rare Dis. 5, 28 (2010).
pubmed: 20946626
pmcid: 2964617
doi: 10.1186/1750-1172-5-28
Bokenkamp, A. et al. Dent-2 disease: a mild variant of Lowe syndrome. J. Pediatr. 155, 94–99 (2009).
pubmed: 19559295
doi: 10.1016/j.jpeds.2009.01.049
Blanchard, A. et al. Observations of a large Dent disease cohort. Kidney Int. 90, 430–439 (2016).
pubmed: 27342959
doi: 10.1016/j.kint.2016.04.022
Prikhodina, L., Papizh, S., Bashirova, Z. & Ludwig, M. Whether women asymptomatic or symptomatic carriers of dent disease? Nephrol. Dial. Transpl. 33, 303 (2018).
doi: 10.1093/ndt/gfy104.FP763
Wrong, O. M., Norden, A. G. W. & Feest, T. G. Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and marked male predominance. Q. J. Med. 87, 473–493 (1994).
Mansour-Hendili, L. et al. Mutation update of the CLCN5 gene responsible for Dent disease 1. Hum. Mutat. 36, 743–752 (2015).
pubmed: 25907713
doi: 10.1002/humu.22804
Pusch, M. & Zifarelli, G. ClC-5: physiological role and biophysical mechanisms. Cell Calcium 58, 57–66 (2015).
pubmed: 25443653
doi: 10.1016/j.ceca.2014.09.007
Nielsen, R., Christensen, E. I. & Birn, H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 89, 58–67 (2016).
pubmed: 26759048
doi: 10.1016/j.kint.2015.11.007
Wang, S. S. et al. Mice lacking renal chloride channel, CLC-5, are a model for Dent’s disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum. Mol. Genet. 9, 2937–2945 (2000).
pubmed: 11115837
doi: 10.1093/hmg/9.20.2937
Levin-Iaina, N. & Dinour, D. Renal disease with OCRL1 mutations: Dent-2 or Lowe syndrome? J. Pediatr. Genet. 1, 3–5 (2012).
pubmed: 27625794
pmcid: 5020912
doi: 10.3233/PGE-2012-002
Suchy, S. F. & Nussbaum, R. L. The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am. J. Hum. Genet. 71, 1420–1427 (2002).
pubmed: 12428211
pmcid: 378584
doi: 10.1086/344517
Blanchard, A. et al. Effect of hydrochlorothiazide on urinary calcium excretion in Dent disease: an uncontrolled trial. Am. J. Kidney Dis. 52, 1084–1095 (2008).
pubmed: 18976849
doi: 10.1053/j.ajkd.2008.08.021
Konrad, M. et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am. J. Hum. Genet. 79, 949–957 (2006).
pubmed: 17033971
pmcid: 1698561
doi: 10.1086/508617
Simon, D. B. et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285, 103–106 (1999).
pubmed: 10390358
doi: 10.1126/science.285.5424.103
Weber, S. et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J. Am. Soc. Nephrol. 12, 1872–1881 (2001).
pubmed: 11518780
doi: 10.1681/ASN.V1291872
Haisch, L., Almeida, J. R., Abreu da Silva, P. R., Schlingmann, K. P. & Konrad, M. The role of tight junctions in paracellular ion transport in the renal tubule: lessons learned from a rare inherited tubular disorder. Am. J. Kidney Dis. 57, 320–330 (2011).
pubmed: 21186073
doi: 10.1053/j.ajkd.2010.08.038
Godron, A. et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin. J. Am. Soc. Nephrol. 7, 801–809 (2012).
pubmed: 22422540
pmcid: 3338284
doi: 10.2215/CJN.12841211
Hampson, G., Konrad, M. A. & Scoble, J. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol. 9, 12 (2008).
pubmed: 18816383
pmcid: 2562370
doi: 10.1186/1471-2369-9-12
Arteaga, M. E., Hunziker, W., Teo, A. S., Hillmer, A. M. & Mutchinick, O. M. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: variable phenotypic expression in three affected sisters from Mexican ancestry. Ren. Fail. 37, 180–183 (2015).
pubmed: 25366522
doi: 10.3109/0886022X.2014.977141
Claverie-Martin, F. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin. Kidney J. 8, 656–664 (2015).
pubmed: 26613020
pmcid: 4655790
doi: 10.1093/ckj/sfv081
Gong, Y. et al. Claudin-14 regulates renal Ca
pubmed: 22373575
pmcid: 3343334
doi: 10.1038/emboj.2012.49
Hou, J. Lecture: new light on the role of claudins in the kidney. Organogenesis 8, 1–9 (2012).
pubmed: 22504740
pmcid: 3399704
doi: 10.4161/org.19808
Karet, F. E. Inherited distal renal tubular acidosis. J. Am. Soc. Nephrol. 13, 2178–2184 (2002).
pubmed: 12138152
doi: 10.1097/01.ASN.0000023433.08833.88
Alexander, R. T., Law, L., Gil-Pena, H., Greenbaum, L. A. & Santos, F. in GeneReviews® (eds M. P. Adam et al.) (1993).
Rungroj, N. et al. Distal renal tubular acidosis caused by tryptophan-aspartate repeat domain 72 (WDR72) mutations. Clin. Genet. 94, 409–418 (2018).
pubmed: 30028003
doi: 10.1111/cge.13418
Jobst-Schwan, T. et al. Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis. Kidney Int. 97, 567–579 (2020).
pubmed: 31959358
doi: 10.1016/j.kint.2019.09.026
Watanabe, T. Improving outcomes for patients with distal renal tubular acidosis: recent advances and challenges ahead. Pediatr. Health Med. Ther. 9, 181–190 (2018).
doi: 10.2147/PHMT.S174459
Besouw, M. T. P. et al. Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr. Nephrol. 32, 987–996 (2017).
pubmed: 28188436
doi: 10.1007/s00467-016-3573-4
Enerback, S. et al. Acidosis and deafness in patients with recessive mutations in FOXI1. J. Am. Soc. Nephrol. 29, 1041–1048 (2018).
pubmed: 29242249
doi: 10.1681/ASN.2017080840
D’Ambrosio, V. et al. Results of a gene panel approach in a cohort of patients with incomplete distal renal tubular acidosis and nephrolithiasis. Kidney Blood Press. Res. 46, 469–474 (2021).
pubmed: 34107482
doi: 10.1159/000516389
Zhang, J. et al. Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 subunit. Am. J. Physiol. Renal Physiol. 307, F1063–F1071 (2014).
pubmed: 25164082
pmcid: 4216985
doi: 10.1152/ajprenal.00408.2014
Bourgeois, S., Bettoni, C., Baron, S. & Wagner, C. A. Haploinsufficiency of the Mouse Atp6v1b1 gene leads to a mild acid-base disturbance with implications for kidney stone disease. Cell Physiol. Biochem. 47, 1095–1107 (2018).
pubmed: 29843146
doi: 10.1159/000490186
Park, E. et al. Genotype-phenotype analysis in pediatric patients with distal renal tubular acidosis. Kidney Blood Press. Res. 43, 513–521 (2018).
pubmed: 29627839
doi: 10.1159/000488698
Sly, W. S. et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N. Engl. J. Med. 313, 139–145 (1985).
pubmed: 3925334
doi: 10.1056/NEJM198507183130302
Venta, P. J., Welty, R. J., Johnson, T. M., Sly, W. S. & Tashian, R. E. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His — Tyr): complete structure of the normal human CA II gene. Am. J. Hum. Genet. 49, 1082–1090 (1991).
pubmed: 1928091
pmcid: 1683243
Whyte, M. P. Carbonic anhydrase II deficiency. Clin. Orthop. Relat. Res. 52–63 (1993).
Bergwitz, C. & Miyamoto, K. I. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch. 471, 149–163 (2019).
pubmed: 30109410
doi: 10.1007/s00424-018-2184-2
Lorenz-Depiereux, B. et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am. J. Hum. Genet. 78, 193–201 (2006).
pubmed: 16358215
doi: 10.1086/499410
Dasgupta, D. et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J. Am. Soc. Nephrol. 25, 2366–2375 (2014).
pubmed: 24700880
pmcid: 4178443
doi: 10.1681/ASN.2013101085
Tieder, M. et al. Hereditary hyporphosphatemic rickets with hypercalciuria. N. Engl. J. Med. 312, 611–617 (1985).
pubmed: 2983203
doi: 10.1056/NEJM198503073121003
Schlingmann, K. P. et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365, 410–421 (2011).
pubmed: 21675912
doi: 10.1056/NEJMoa1103864
De Paolis, E., Scaglione, G. L., De Bonis, M., Minucci, A. & Capoluongo, E. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype. Clin. Chem. Lab. Med. 57, 1650–1667 (2019).
pubmed: 31188746
doi: 10.1515/cclm-2018-1208
Tebben, P. J. et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J. Clin. Endocrinol. Metab. 97, E423–E427 (2012).
pubmed: 22337913
pmcid: 3319216
doi: 10.1210/jc.2011-1935
Tebben, P. J., Singh, R. J. & Kumar, R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr. Rev. 37, 521–547 (2016).
pubmed: 27588937
pmcid: 5045493
doi: 10.1210/er.2016-1070
Carpenter, T. O. Take another CYP: confirming a novel mechanism for “idiopathic” hypercalcemia. J. Clin. Endocrinol. Metab. 97, 768–771 (2012).
pubmed: 22392954
pmcid: 3319214
doi: 10.1210/jc.2012-1110
Nesterova, G. et al. 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin. J. Am. Soc. Nephrol. 8, 649–657 (2013).
pubmed: 23293122
pmcid: 3613951
doi: 10.2215/CJN.05360512
Schlingmann, K. P., Cassar, W. & Konrad, M. Juvenile onset IIH and CYP24A1 mutations. Bone Rep. 9, 42–46 (2018).
pubmed: 30591926
pmcid: 6303532
doi: 10.1016/j.bonr.2018.06.005
Hawkes, C. P. et al. CYP3A4 induction by rifampin: an alternative pathway for Vitamin D inactivation in patients with CYP24A1 mutations. J. Clin. Endocrinol. Metab. 102, 1440–1446 (2017).
pubmed: 28324001
pmcid: 5443336
doi: 10.1210/jc.2016-4048
Sayers, J. Adrian Stokes and the portrait of Melanie Klein. Int. J. Psychoanal. 96, 1013–1024 (2015).
pubmed: 25989030
doi: 10.1111/1745-8315.12333
Schlingmann, K. P. et al. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J. Am. Soc. Nephrol. 27, 604–614 (2016).
pubmed: 26047794
doi: 10.1681/ASN.2014101025
Wagner, C. A., Rubio-Aliaga, I. & Hernando, N. Renal phosphate handling and inherited disorders of phosphate reabsorption: an update. Pediatr. Nephrol. 34, 549–559 (2019).
pubmed: 29275531
doi: 10.1007/s00467-017-3873-3
Amar, A. et al. Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. Hum. Genet. 138, 211–219 (2019).
pubmed: 30778725
pmcid: 6426152
doi: 10.1007/s00439-019-01978-x
Kang, S. J., Lee, R. & Kim, H. S. Infantile hypercalcemia with novel compound heterozygous mutation in SLC34A1 encoding renal sodium-phosphate cotransporter 2a: a case report. Ann. Pediatr. Endocrinol. Metab. 24, 64–67 (2019).
pubmed: 30943683
pmcid: 6449619
doi: 10.6065/apem.2019.24.1.64
Policastro, L. J., Saggi, S. J., Goldfarb, D. S. & Weiss, J. P. Personalized intervention in monogenic stone formers. J. Urol. 199, 623–632 (2018).
pubmed: 29061541
doi: 10.1016/j.juro.2017.09.143
Oliveira, B., Kleta, R., Bockenhauer, D. & Walsh, S. B. Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am. J. Physiol. Renal Physiol. 311, F1243–F1252 (2016).
pubmed: 27605580
doi: 10.1152/ajprenal.00211.2016
Simon, D. B. et al. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat. Genet. 14, 152–156 (1996).
pubmed: 8841184
doi: 10.1038/ng1096-152
Simon, D. B. et al. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 13, 183–188 (1996).
pubmed: 8640224
doi: 10.1038/ng0696-183
Gollasch, B., Anistan, Y. M., Canaan-Kuhl, S. & Gollasch, M. Late-onset Bartter syndrome type II. Clin. Kidney J. 10, 594–599 (2017).
pubmed: 28979772
pmcid: 5622898
doi: 10.1093/ckj/sfx033
Huang, L. et al. Nephrocalcinosis as adult presentation of Bartter syndrome type II. Neth. J. Med. 72, 91–93 (2014).
pubmed: 24659592
Simon, D. B. et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat. Genet. 17, 171–178 (1997).
pubmed: 9326936
doi: 10.1038/ng1097-171
Brochard, K. et al. Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol. Dial. Transpl. 24, 1455–1464 (2009).
doi: 10.1093/ndt/gfn689
Jeck, N. et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 108, E5 (2001).
pubmed: 11433084
doi: 10.1542/peds.108.1.e5
Schlingmann, K. P. et al. Salt wasting and deafness resulting from mutations in two chloride channels. N. Engl. J. Med. 350, 1314–1319 (2004).
pubmed: 15044642
doi: 10.1056/NEJMoa032843
Laghmani, K. et al. Polyhydramnios, transient antenatal Bartter’s syndrome, and MAGED2 mutations. N. Engl. J. Med. 374, 1853–1863 (2016).
pubmed: 27120771
doi: 10.1056/NEJMoa1507629
Pearce, S. H. S. et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115–1122 (1996).
pubmed: 8813042
doi: 10.1056/NEJM199610103351505
Hannan, F. M. et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum. Mol. Genet. 21, 2768–2778 (2012).
pubmed: 22422767
doi: 10.1093/hmg/dds105
Hannan, F. M., Kallay, E., Chang, W., Brandi, M. L. & Thakker, R. V. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 15, 33–51 (2018).
pubmed: 30443043
pmcid: 6535143
doi: 10.1038/s41574-018-0115-0
Hannan, F. M. & Thakker, R. V. Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 359–371 (2013).
pubmed: 23856265
doi: 10.1016/j.beem.2013.04.007
Hussain, A., Atlani, M., Goyal, A. & Khurana, A. K. Type-5 Bartter syndrome presenting with metabolic seizure in adulthood. BMJ Case Rep. 14, e235349 (2021).
pubmed: 33597159
doi: 10.1136/bcr-2020-235349
Nesbit, M. A. et al. Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368, 2476–2486 (2013).
pubmed: 23802516
pmcid: 3773604
doi: 10.1056/NEJMoa1300253
Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649–658 (2013).
pubmed: 23944302
doi: 10.1056/NEJMra1301564
Hoppe, B. An update on primary hyperoxaluria. Nat. Rev. Nephrol. 8, 467–475 (2012).
pubmed: 22688746
doi: 10.1038/nrneph.2012.113
Lieske, J. C., Spargo, B. H. & Toback, F. G. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J. Urol. 148, 1517–1519 (1992).
pubmed: 1433562
doi: 10.1016/S0022-5347(17)36954-9
Milliner, D. S., Harris, P. C., Cogal, A. G. & Lieske, J. C. in GeneReviews® (eds M. P. Adam et al.) (1993).
Danpure, C. J. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am. J. Nephrol. 25, 303–310 (2005).
pubmed: 15961951
doi: 10.1159/000086362
Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559–2570 (2015).
pubmed: 25644115
pmcid: 4587693
doi: 10.1681/ASN.2014070698
Danpure, C. J. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim. Biophys. Acta 1763, 1776–1784 (2006).
pubmed: 17027096
doi: 10.1016/j.bbamcr.2006.08.021
Martin-Higueras, C., Torres, A. & Salido, E. Molecular therapy of primary hyperoxaluria. J. Inherit. Metab. Dis. 40, 481–489 (2017).
pubmed: 28425073
doi: 10.1007/s10545-017-0045-3
Fargue, S., Lewin, J., Rumsby, G. & Danpure, C. J. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J. Biol. Chem. 288, 2475–2484 (2013).
pubmed: 23229545
doi: 10.1074/jbc.M112.432617
Beck, B. B., Hoyer-Kuhn, H., Gobel, H., Habbig, S. & Hoppe, B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin. Investig. Drugs 22, 117–129 (2013).
pubmed: 23167815
doi: 10.1517/13543784.2013.741587
Monico, C. G., Olson, J. B. & Milliner, D. S. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am. J. Nephrol. 25, 183–188 (2005).
pubmed: 15849466
doi: 10.1159/000085411
Singh, P. et al. Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical) AGXT gene mutation. Kidney Int. Rep. 5, 955–958 (2020).
pubmed: 32518881
pmcid: 7270974
doi: 10.1016/j.ekir.2020.04.004
Cramer, S. D., Ferree, P. M., Lin, K., Milliner, D. S. & Holmes, R. P. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II [published erratum appears in Hum Mol Genet 1999 Dec;8(13):2574]. Hum. Mol. Genet. 8, 2063–2069 (1999).
pubmed: 10484776
doi: 10.1093/hmg/8.11.2063
Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389–1399 (2019).
pubmed: 31685312
doi: 10.1016/j.kint.2019.08.018
Milliner, D. S., Wilson, D. M. & Smith, L. H. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 59, 31–36 (2001).
pubmed: 11135054
doi: 10.1046/j.1523-1755.2001.00462.x
Milliner, D. S., Harris, P. C. & Lieske, J. C. in GeneReviews® (eds M. P. Adam et al.) (1993).
Beck, B. B. et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur. J. Hum. Genet. 21, 162–172 (2013).
pubmed: 22781098
doi: 10.1038/ejhg.2012.139
Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392–399 (2010).
pubmed: 20797690
pmcid: 2933339
doi: 10.1016/j.ajhg.2010.07.023
Ventzke, A. et al. Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatr. Nephrol. 32, 2263–2271 (2017).
pubmed: 28711958
doi: 10.1007/s00467-017-3731-3
Greed, L. et al. Metabolite diagnosis of primary hyperoxaluria type 3. Pediatr. Nephrol. 33, 1443–1446 (2018).
pubmed: 29705963
doi: 10.1007/s00467-018-3967-6
Allard, L. et al. Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr. Nephrol. 30, 1807–1813 (2015).
pubmed: 25972204
doi: 10.1007/s00467-015-3090-x
Compagnon, P. et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 20, 1475–1485 (2014).
pubmed: 25267365
Weigert, A., Martin-Higueras, C. & Hoppe, B. Novel therapeutic approaches in primary hyperoxaluria. Expert Opin. Emerg. Drugs 23, 349–357 (2018).
pubmed: 30540923
doi: 10.1080/14728214.2018.1552940
Hulton, S. A. The primary hyperoxalurias: a practical approach to diagnosis and treatment. Int. J. Surg. 36, 649–654 (2016).
pubmed: 27815184
doi: 10.1016/j.ijsu.2016.10.039
Knoll, T., Zollner, A., Wendt-Nordahl, G., Michel, M. S. & Alken, P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr. Nephrol. 20, 19–24 (2005).
pubmed: 15602663
doi: 10.1007/s00467-004-1663-1
Calonge, M. J. et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat. Genet. 6, 420–425 (1994).
pubmed: 8054986
doi: 10.1038/ng0494-420
Feliubadalo, L. et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b
pubmed: 10471498
doi: 10.1038/12652
Rhodes, H. L. et al. Clinical and genetic analysis of patients with cystinuria in the United Kingdom. Clin. J. Am. Soc. Nephrol. 10, 1235–1245 (2015).
pubmed: 25964309
pmcid: 4491297
doi: 10.2215/CJN.10981114
Chow, G. K. & Streem, S. B. Medical treatment of cystinuria: results of contemporary clinical practice. J. Urol. 156, 1576–1578 (1996).
pubmed: 8863541
doi: 10.1016/S0022-5347(01)65451-X
Bollee, G. et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J. Am. Soc. Nephrol. 21, 679–688 (2010).
pubmed: 20150536
pmcid: 2844298
doi: 10.1681/ASN.2009080808
Runolfsdottir, H. L., Palsson, R., Agustsdottir, I. M., Indridason, O. S. & Edvardsson, V. O. Kidney disease in adenine phosphoribosyltransferase deficiency. Am. J. Kidney Dis. 67, 431–438 (2016).
pubmed: 26724837
doi: 10.1053/j.ajkd.2015.10.023
Edvardsson, V., Palsson, R., Olafsson, I., Hjaltadottir, G. & Laxdal, T. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland. Am. J. Kidney Dis. 38, 473–480 (2001).
pubmed: 11532677
doi: 10.1053/ajkd.2001.26826
Kamatani, N., Hakoda, M., Otsuka, S., Yoshikawa, H. & Kashiwazaki, S. Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients. J. Clin. Invest. 90, 130–135 (1992).
pubmed: 1353080
pmcid: 443071
doi: 10.1172/JCI115825
Harambat, J., Bollee, G., Daudon, M., Ceballos-Picot, I. & Bensman, A. Adenine phosphoribosyltransferase deficiency in children. Pediatr. Nephrol. 27, 571–579 (2012).
pubmed: 22212387
doi: 10.1007/s00467-011-2037-0
Edvardsson, V. O. et al. Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency (APRTd): a clinical trial. Eur. J. Intern. Med. 48, 75–79 (2018).
pubmed: 29241594
doi: 10.1016/j.ejim.2017.10.007
Ichida, K. et al. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J. Clin. Invest. 99, 2391–2397 (1997).
pubmed: 9153281
pmcid: 508078
doi: 10.1172/JCI119421
Ichida, K., Matsumura, T., Sakuma, R., Hosoya, T. & Nishino, T. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem. Biophys. Res. Commun. 282, 1194–1200 (2001).
pubmed: 11302742
doi: 10.1006/bbrc.2001.4719
Zaki, M. S. et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: clinical and molecular spectrum among Egyptian patients. Eur. J. Paediatr. Neurol. 20, 714–722 (2016).
pubmed: 27289259
pmcid: 4993451
doi: 10.1016/j.ejpn.2016.05.011
Nagae, A. et al. Asymptomatic hereditary xanthinuria: a case report. Jpn. J. Med. 29, 287–291 (1990).
pubmed: 2273608
doi: 10.2169/internalmedicine1962.29.287
Reiss, J. & Hahnewald, R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum. Mutat. 32, 10–18 (2011).
pubmed: 21031595
doi: 10.1002/humu.21390
Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. Nat. Rev. Urol. 17, 407–421 (2020).
pubmed: 32533118
doi: 10.1038/s41585-020-0332-x
Thorleifsson, G. et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat. Genet. 41, 926–930 (2009).
pubmed: 19561606
doi: 10.1038/ng.404
Oddsson, A. et al. Common and rare variants associated with kidney stones and biochemical traits. Nat. Commun. 6, 7975 (2015).
pubmed: 26272126
doi: 10.1038/ncomms8975
Palsson, R., Indridason, O. S., Edvardsson, V. O. & Oddsson, A. Genetics of common complex kidney stone disease: insights from genome-wide association studies. Urolithiasis 47, 11–21 (2019).
pubmed: 30523390
doi: 10.1007/s00240-018-1094-2
Curry, J. N. et al. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J. Clin. Invest. 130, 1948–1960 (2020).
pubmed: 32149733
pmcid: 7108907
doi: 10.1172/JCI127750
Muto, S. et al. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc. Natl Acad. Sci. USA 107, 8011–8016 (2010).
pubmed: 20385797
pmcid: 2867900
doi: 10.1073/pnas.0912901107
Worcester, E. M. et al. Evidence for increased postprandial distal nephron calcium delivery in hypercalciuric stone-forming patients. Am. J. Physiol. Renal Physiol. 295, F1286–F1294 (2008).
pubmed: 18715937
pmcid: 2584913
doi: 10.1152/ajprenal.90404.2008
Devuyst, O., Olinger, E. & Rampoldi, L. Uromodulin: from physiology to rare and complex kidney disorders. Nat. Rev. Nephrol. 13, 525–544 (2017).
pubmed: 28781372
doi: 10.1038/nrneph.2017.101
Gudbjartsson, D. F. et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet. 6, e1001039 (2010).
pubmed: 20686651
pmcid: 2912386
doi: 10.1371/journal.pgen.1001039
Devuyst, O. et al. Autosomal dominant tubulointerstitial kidney disease. Nat. Rev. Dis. Prim. 5, 60 (2019).
pubmed: 31488840
doi: 10.1038/s41572-019-0109-9
Hoenderop, J. G. et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J. Clin. Invest. 112, 1906–1914 (2003).
pubmed: 14679186
pmcid: 297001
doi: 10.1172/JCI200319826
Hoenderop, J. G. J. et al. Localization of the epithelial Ca
pubmed: 10864572
doi: 10.1681/ASN.V1171171
Moor, M. B. & Bonny, O. Ways of calcium reabsorption in the kidney. Am. J. Physiol. Renal Physiol. 310, F1337–F1350 (2016).
pubmed: 27009338
doi: 10.1152/ajprenal.00273.2015
Urabe, Y. et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet. 8, e1002541 (2012).
pubmed: 22396660
pmcid: 3291538
doi: 10.1371/journal.pgen.1002541
Li, X. et al. Common variants in ALPL gene contribute to the risk of kidney stones in the Han Chinese population. Genet. Test. Mol. Biomark. 22, 187–192 (2018).
doi: 10.1089/gtmb.2017.0208
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat. Commun. 10, 5175 (2019).
pubmed: 31729369
pmcid: 6858460
doi: 10.1038/s41467-019-13145-x
Paranjpe, I. et al. Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis. Kidney Int. 98, 1323–1330 (2020).
pubmed: 32540406
pmcid: 7606592
doi: 10.1016/j.kint.2020.04.055
Zaidi, S. K. et al. Mitotic bookmarking of genes: a novel dimension to epigenetic control. Nat. Rev. Genet. 11, 583–589 (2010).
pubmed: 20628351
pmcid: 3033599
doi: 10.1038/nrg2827